Get instant alerts when breaking news about your stock. Claim your 1 week free trial Street Insider Premium here.
MENLO PARK, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit”, “we” or “Company”) today announced Dr. Alessandra Cesano, MD, Ph.D. No. and appointed to the Board of Directors, effective immediately.
“Dr. Summit Chairman and Chief Executive Officer Robert W. Duggan said, “As we plan to expand our pipeline product portfolio into oncology, Alessandra will We are pleased to add the wisdom and expertise that we bring to our excellent management team.Her experience in developing both large and small molecules in solid tumors will benefit our team’s expertise in our focus areas of business development activities. Her wealth of experience will be invaluable to those of us looking to develop and advance medical therapies to the next level in oncology as part of the next chapter of the Team Summit.
Dr. Cesano is Chief Medical Officer (CMO) of Essa Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company developing new therapies to treat prostate cancer. Previously, he served as CMO at NanoString Inc. and Cleave Biosciences. She has her 25 years of experience in the biopharmaceutical industry with a focus on oncology, including her extensive experience at Biogen, Amgen and GSK. She was instrumental in the development and approval of two of her over-the-counter medicines, including her Vectibix® (panitumumab), an anti-EGFR antibody, for the treatment of certain colorectal cancers. Dr. Cesano currently serves on the board of directors of Puma Biotechnology Inc. (NASDAQ: PBYI), a clinical-stage oncology company focused on solid tumors. She graduated from the University of Turin with a PhD in Tumor Immunology and her MD. She is a Board Certified Oncologist in Europe.
“I am truly delighted to be part of a team summit aimed at combating this horrific disease and making a meaningful impact on the lives of cancer patients who face incredible challenges,” said Dr. Cesano. I was. “I have spent much of my life aligned with Summit’s mission and goals: to make patients’, physicians’, caregivers’, and society-friendly’ advances in oncology a priority. We are excited to work with this extraordinary group of leaders to truly transform the patient landscape with therapies that improve both quality and longevity.”
Summit Therapeutics Mission StatementTake full responsibility for the design, development, conduct and registration of trials, regulatory submissions and approvals, and successful commercialization of patient, physician, caregiver and society friendly medical therapies to: Building a viable, long-term health care organization: improving quality of life, extending potential lifespans and solving critical medical needs. Identify and manage promising product candidates based on strong scientific development and management expertise, develop products in a rapid and cost-effective manner, and collaborate with commercial and/or development partners as needed do.
We accomplish this by building a team of world-class professional scientists and business managers who apply their experience and knowledge to this mission. We exist to chart, strategize and execute on medical treatments that position us for market share and leadership positions. Team Summit takes full responsibility for facilitating the continued expansion of knowledge, competence, competence and well-being for all involved stakeholders and highly valued shareholders.
About Summit TherapeuticsSummit was founded in 2003 and is publicly traded on the Nasdaq Global Market (symbol “SMMT”). The company is headquartered in Menlo Park, CA, with offices in Oxford, UK and Cambridge, UK. For more information, visit https://www.summittxinc.com and follow us on Twitter @summitplc.
Summit Investor Contact:Dave GancarzHead of Stakeholder Relations & Corporate Strategy[email protected]
General inquiries: [email protected]
Summit Forward-Looking Statementsour future expectations, plans and Statements in this press release regarding forward-looking statements. Product Candidates, Timing of Initiation, Completion and Availability of Data from Clinical Trials, Potential Marketing Authorization Applications, Impact of the COVID-19 Pandemic on Our Business and Clinical Trials, Potential Acquisitions, and the following words: Other statements including “anticipate”, “believe”, “continue”, “may”, “estimate”, “expect”, “intend”, “may”, “plan “will,” “could,” “predict,” “predict,” “should,” “target,” “would,” and similar expressions are defined in the Private Securities Litigation Reform of 1995. It constitutes forward-looking statements within the meaning of the law. Actual results may differ materially. As a result of a variety of important factors, including the topline results of our Phase 3 Ri-CoDIFy trial evaluating ridinirazole and the evaluation of underlying data related to the results of regulatory consultations, such Indicated by forward-looking statements. including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, the availability and timing of data from ongoing and future clinical trials, the results of such trials and their success, and the coronavirus COVID. Whether the preliminary results of a clinical trial involving a global public health crisis predict the final outcome of that trial, or whether the results of an early clinical or preclinical trial indicate a result. results of future clinical trials, whether business development opportunities expand our pipeline, including but not limited to potential acquisitions and/or collaborations with other entities; expectations, laws and regulations affecting government contracts and financing, the availability of sufficient funds for our foreseeable and unforeseen operating expenses, and the “ capital expenditure requirements and other factors described in the Risk Factors section. Any changes to ongoing trials would not only affect the likelihood of successful completion of clinical development of lisinirazole, but also cause delays, impact future costs and add uncertainty to commercialization efforts. sex may be added. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements contained in this press release represent the company’s views as of the date of this release and should not be relied upon as representing the company’s views at any later date. We expressly disclaim any obligation to update any forward-looking statements contained in this press release.
Source: Summit Therapeutics, Inc.
